Form 4: Ionis Pharmaceuticals Director Spencer R. Berthelsen Receives Stock Options and Restricted Stock Units

Director Spencer R. Berthelsen received stock options and restricted stock units from Ionis Pharmaceuticals as part of their non-employee director compensation policy.

Summary

• On July 1, 2024, Spencer R. Berthelsen, a director of Ionis Pharmaceuticals, received stock options for 10,111 shares and 4,079 restricted stock units (RSUs).
• The grants were adjusted to ensure the director's annual equity compensation does not exceed $450,000.
• The stock options have an exercise price of $47.11 and vest 100% on either the first anniversary of the grant date or the next annual meeting, expiring on June 30, 2034.
• The RSUs also vest 100% on the first anniversary of the grant date or the next annual meeting and will be delivered on July 15th following the vesting date.

Sentiment

Score: 7

Explanation: The document reflects a routine equity grant to a director, indicating standard corporate governance practices. The sentiment is neutral to slightly positive as it aligns director interests with shareholders.

Positives

• The equity grants align the director's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Industry Context

Equity compensation is a common practice for compensating board members in publicly traded companies, aligning their interests with shareholders and incentivizing long-term value creation. The specific amount and type of equity granted can vary based on company size, industry, and individual director responsibilities.

Comparison to Industry Standards

• Director compensation packages vary widely across the pharmaceutical industry.
• Companies like Amgen, Gilead, and Biogen also utilize a mix of cash and equity to compensate their directors.
• The $450,000 cap on annual equity compensation appears to be within a reasonable range for a company of Ionis's size and market capitalization, but a more detailed benchmarking analysis would be required to confirm this.

Stakeholder Impact

• The equity grants align the director's interests with those of the shareholders, potentially leading to better decision-making.
• The grants have no immediate impact on employees, customers, suppliers, or creditors.

Key Dates